{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 44 of 92', 'CR845-CLIN3102', '6.5.2', 'Schedule of Events for the Open-label Extension Phase', 'Study procedures for the Open-label Extension Phase are summarized in Table 3.', 'The safety assessment visit may occur on any chosen dialysis day of a scheduled week as', 'long as all assessments are completed during that visit. Patients who miss one of the', 'scheduled study visit weeks (eg, Week 4 of open-label treatment) may complete this visit', 'at their next dialysis treatment if conducted within 2 weeks of the scheduled visit.', 'Unscheduled visits may be necessary for outstanding, unresolved adverse events', '(eg, additional safety laboratory or clinical evaluations). At minimum, for any', 'unscheduled visit, the reason for the visit will be recorded, the adverse events reported, as', 'well as changes to concomitant medications, as applicable. Additional testing', '(eg, laboratory tests, vital signs, ECGs) will be performed as clinically indicated.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 46 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 45 of 92', 'CR845-CLIN3102', 'Table 3.', 'Schedule of Events: Open-label Extension Phase', 'Open-label Treatment Perioda Up to 52 Weeks of Dosing', 'Follow-Up', 'First Dialysis of', 'Week 53b', '7 - 10 days after End of', 'End of Treatment', 'Treatment/Early', 'Termination', 'Study Procedures', 'Day 1c', 'Week 4', 'Week 8', 'Week 12a', 'Week 24', 'Week 36a', '/Early Termination', 'Administrative procedures', 'Inclusion/exclusion criteria', 'Safety and other evaluations', 'Physical examination', 'Record prescription dry body weighte', 'Record every 12 weekse', 'Pre-dialysis 12-lead electrocardiogram\u00b2', 'X', 'Pre-dialysis vital signs', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Hematology, serum chemistry', 'X', 'X', 'X', '(pre-dialysis)', 'Serum pregnancy test for women of', 'X', 'X', 'childbearing potential only', 'Record dose of ESA and IV iron', 'X', 'Record on ongoing basish', 'Record number of missed dialysis visits', 'Record on an ongoing basis', 'and reason(s), as applicable', 'IV administration of study drug', 'X\u00b9', 'Dose after each dialysis up to Week 52 included\u00b9', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 47 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 46 of 92', 'CR845-CLIN3102', 'Table 3.', 'Schedule of Events: Open-label Extension Phase', '(Continued)', 'Open-label Treatment Perioda Up to 52 Weeks of Dosing', 'Follow-Up', 'First Dialysis of Week', '53b', '7 - 10 days after End of', 'Treatment/Early', 'End of Treatment /Early', 'Termination', 'Study Procedures', 'Day 1c', 'Week 4', 'Week 8', 'Week 12a', 'Week 24', 'Week 36a', 'Termination', 'Safety and other evaluations', '5-D itch scale\u00b9', 'X', 'X', 'X', 'X', 'X', 'X', 'Inflammatory biomarker samples*', 'X', 'X', 'Adverse event monitoring', 'Record on an ongoing basis\u00b9', 'Concomitant medications (including', 'antipruritic medications)', 'Record on an ongoing basis\u00b9', 'ESA = erythropoiesis-stimulating agent; IV = intravenous', 'a.', \"Each visit during the Open-label Treatment Period will coincide with the patient's normal dialysis treatments. The study visit may occur on any chosen dialysis day of a\", 'scheduled week as long as all assessments are completed during that visit. Patients who miss one of the scheduled study visit weeks (eg, Week 4) may complete the visit', 'procedures for this visit at their next dialysis treatment as long as it is within 2 weeks of the originally scheduled visit date.', 'b.', 'The End-of-Treatment Visit will be the first dialysis visit following the last dose of study drug (ie, first dialysis on Week 53).', 'c.', 'Day', '1 of the Open-label Treatment Period corresponds to the week after the Discontinuation Period of the Double-blind Phase (+1 week window allowed).', 'd. Prior to dosing on Day 1 of the Open-label Treatment Period, the inclusion/exclusion criteria will be confirmed.', 'e.', 'The prescription dry body weight will be captured from the dialysis prescription and will be recorded on Day 1 and every 12 weeks during the Open-label Treatment Period', '(during Weeks 12, 24, 36, and 48). If there is a >10% change in prescription dry body weight, then the CR845 dose will be adjusted. The date of prescription dry body', 'weight change will also be recorded.', 'f.', 'Electrocardiogram must be performed prior to the start of dialysis.', 'g.', 'Vital signs, including body temperature, heart rate, and blood pressure, will be obtained at the specified visits while the patient is in a sitting or semi-recumbent position prior', 'to the start of dialysis. Heart rate will be measured at each dialysis; if the heart rate is clinically significant and outside the prespecified visits per Schedule of Events the heart', 'rate will be recorded on the relevant CRF page.', 'h.', 'Doses of ESA and IV iron administered will be recorded for the 4-week period ending on Weeks 4 (Day 1 to Week 4), 12 (Week 9 to 12), 24 (Week 21 to 24), 36 (Week 33 to', '36), and 52 (Week 49 to 52) or for the 4 weeks before Early Termination Visit. Preferably record at the end of the specified week, which corresponds to the beginning of the', 'following calendar week (ie, end of Week 4 is the Monday/Tuesday of Week 5)', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 48 of 95']\n\n###\n\n", "completion": "END"}